PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32752896-3 2020 When compared to the modest selectivity index of rasagiline (II, a well-known MAO-B inhibitor, SI > 50), both 4b and 4e also showed better selectivity indices (SI > 60 and 120, respectively). rasagiline 49-59 monoamine oxidase B Homo sapiens 78-83 33375412-3 2020 Considering these results, we wanted to take benefit of the structural analogy lying in donepezil (DPZ) and rasagiline, two indane derivatives marketed as AChE and MAO-B inhibitors, respectively, and to propose the synthesis and the preliminary in vitro biological characterization of a structural compromise between these two compounds, we called propargylaminodonepezil (PADPZ). rasagiline 108-118 monoamine oxidase B Homo sapiens 164-169 2420928-5 1986 N-Desmethylpropargylindane hydrochloride (AGN 1135) was also shown to have MAO-B inhibitory selectivity similar to that of l-deprenyl. rasagiline 42-50 monoamine oxidase B Homo sapiens 75-80 33887441-3 2021 Herein we report 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as hMAO-B inhibitors, which were designed by employing a fragment-based drug design strategy to link rasagiline to hydrophobic fragments. rasagiline 184-194 monoamine oxidase B Homo sapiens 86-92 32652406-0 2020 Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-beta aggregation against Alzheimer"s disease. rasagiline 47-57 monoamine oxidase B Homo sapiens 105-124 32858935-0 2020 Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study. rasagiline 103-113 monoamine oxidase B Homo sapiens 80-99 32250219-5 2020 TV-3326 combines the neurorestorative/neuroprotective actions of the cholinesterase (ChE) inhibitory activity of rivastigmine with rasagiline (a selective monoamine oxidase-B inhibitor and novel antiparkinsonian agent) in a single molecule. rasagiline 131-141 monoamine oxidase B Homo sapiens 155-174 32037726-0 2020 Coumarin-rasagiline hybrids as potent and selective hMAO-B inhibitors, antioxidants and neuroprotective agents. rasagiline 0-19 monoamine oxidase B Homo sapiens 52-58 31264403-3 2019 Still, despite this practical importance, the precise chemical mechanisms underlying the irreversible inhibition of the MAO B isoform with clinical drugs rasagiline (RAS) and selegiline (SEL) remained unknown. rasagiline 154-164 monoamine oxidase B Homo sapiens 120-125 32378642-5 2020 Rasagiline is a potent and specific MAO-B inhibitor and is currently approved as an antiparkinsonian drug in more than 50 countries, including the United States and European countries. rasagiline 0-10 monoamine oxidase B Homo sapiens 36-41 31421966-1 2019 The irreversible monoamine oxidase B (MAO B) inhibitor rasagiline has been described with multiple disease modifying effects in vitro on models of Parkinson"s disease. rasagiline 55-65 monoamine oxidase B Homo sapiens 17-36 31421966-1 2019 The irreversible monoamine oxidase B (MAO B) inhibitor rasagiline has been described with multiple disease modifying effects in vitro on models of Parkinson"s disease. rasagiline 55-65 monoamine oxidase B Homo sapiens 38-43 30877626-1 2019 Rasagiline mesylate is an irreversible MAO-B inhibitor which requires daily oral administration for treatment of Parkinson"s disease due to its short half-life. rasagiline 0-10 monoamine oxidase B Homo sapiens 39-44 31264403-3 2019 Still, despite this practical importance, the precise chemical mechanisms underlying the irreversible inhibition of the MAO B isoform with clinical drugs rasagiline (RAS) and selegiline (SEL) remained unknown. rasagiline 166-169 monoamine oxidase B Homo sapiens 120-125 30689042-1 2019 Rasagiline is a monoamine oxidase B inhibitor with demonstrated efficacy and safety in patients with Parkinson"s disease (PD). rasagiline 0-10 monoamine oxidase B Homo sapiens 16-35 30160213-4 2019 Selegiline and rasagiline are irreversible inhibitors forming a covalent bond within the active site of MAOB. rasagiline 15-25 monoamine oxidase B Homo sapiens 104-108 30192007-1 2019 INTRODUCTION: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS). rasagiline 14-24 monoamine oxidase B Homo sapiens 30-49 30192007-1 2019 INTRODUCTION: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS). rasagiline 14-24 monoamine oxidase B Homo sapiens 51-56 30205936-1 2019 BACKGROUND: Rasagiline is a monoamine oxidase type-B inhibitor in development in Japan for Parkinson"s disease (PD). rasagiline 12-22 monoamine oxidase B Homo sapiens 28-52 30534374-1 2018 Background: Rasagiline is a monoamine oxidase-B inhibitor used for Parkinson"s disease (PD) treatment, but its effectiveness on Chinese patients is unclear. rasagiline 12-22 monoamine oxidase B Homo sapiens 28-47 31795034-0 2019 Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy. rasagiline 0-10 monoamine oxidase B Homo sapiens 14-33 31795034-3 2019 OBJECTIVES: To test the hypothesis that the MAO-B inhibitor, rasagiline reduces [18F]THK5351 uptake in PSP. rasagiline 61-71 monoamine oxidase B Homo sapiens 44-49 30341696-6 2018 Selective inhibitors of MAO-B (selegiline, rasagiline and safinamide) have found a therapeutic role in the treatment of Parkinson"s disease and reversible inhibitors of MAO-A offered antidepressant activity without the serious side effects of the earlier nonselective MAO inhibitors. rasagiline 43-53 monoamine oxidase B Homo sapiens 24-29 29279995-7 2018 MAO-B inhibitors selegiline and rasagiline protect neurons via increase expression of anti-apoptotic Bcl-2 and pro-survival neurotrophic factors in human neuroblastoma SH-SY5Y and glioblastoma U118MG cell lines. rasagiline 32-42 monoamine oxidase B Homo sapiens 0-5 29417334-0 2018 Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson"s disease. rasagiline 104-114 monoamine oxidase B Homo sapiens 71-76 29417334-8 2018 The second MAO-B inhibitor approved for the treatment of Parkinson"s disease, rasagiline also possesses this structural element and shows similar pharmacological characteristics. rasagiline 78-88 monoamine oxidase B Homo sapiens 11-16 29477356-2 2018 The objective of this study was to investigate anodal co-iontophoresis of pramipexole (PRAM; dopamine agonist) and rasagiline (RAS; MAO-B inhibitor) in vitro and in vivo. rasagiline 127-130 monoamine oxidase B Homo sapiens 132-137 29956417-11 2018 Long-term administration of rasagiline can increase colonic DA thereby inhibiting colonic motility, suggesting that colonic MAO-B could be a potential drug target for colonic dysmotility. rasagiline 28-38 monoamine oxidase B Homo sapiens 124-129 29847694-11 2018 When ranking the MAO-B inhibitors given in combination with levodopa, selegiline was the most effective and rasagiline was the second best. rasagiline 108-118 monoamine oxidase B Homo sapiens 17-22 29748109-1 2018 INTRODUCTION: Rasagiline, a selective, irreversible monoamine oxidase-B inhibitor, is in development in Japan as adjunctive therapy to levodopa. rasagiline 14-24 monoamine oxidase B Homo sapiens 52-71 28577058-2 2017 MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neurons in animal and cellular models of neurodegeneration. rasagiline 18-28 monoamine oxidase B Homo sapiens 0-5 29955193-7 2018 Data Synthesis: The search identified 8 studies evaluating the potential interaction between SSRIs and the MAO-B inhibitors selegiline and rasagiline. rasagiline 139-149 monoamine oxidase B Homo sapiens 107-112 29339253-0 2018 Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline. rasagiline 157-167 monoamine oxidase B Homo sapiens 117-136 29339253-2 2018 Herein we report rasagiline derivatives as novel potent and selective hMAO-B inhibitors. rasagiline 17-27 monoamine oxidase B Homo sapiens 70-76 29339253-3 2018 They were designed by employing fragment-based drug design strategy to link rasagiline and hydrophobic fragments, which may target a hydrophobic pocket in the entrance cavity of hMAO-B. rasagiline 76-86 monoamine oxidase B Homo sapiens 178-184 29339253-5 2018 A promising selective hMAO-B inhibitor D14 with similar inhibitory activity as rasagiline and improved isoform selectivity was yielded. rasagiline 79-89 monoamine oxidase B Homo sapiens 22-28 28923922-8 2017 Accordingly, MAO-B inhibitor rasagiline disrupts alpha-Syn/TrkB complex and rescues TrkB neurotrophic signaling, preventing alpha-Syn-induced dopaminergic neuronal death and restoring motor functions. rasagiline 29-39 monoamine oxidase B Homo sapiens 13-18 28682929-2 2017 Rasagiline is an irreversible inhibitor of monoamine oxidase B. rasagiline 0-10 monoamine oxidase B Homo sapiens 43-62 28682929-6 2017 Patients on rasagiline or safinamide showed lower monoamine oxidase-B enzyme activity compared with patients without monoamine oxidase B inhibitor intake. rasagiline 12-22 monoamine oxidase B Homo sapiens 50-69 28682929-6 2017 Patients on rasagiline or safinamide showed lower monoamine oxidase-B enzyme activity compared with patients without monoamine oxidase B inhibitor intake. rasagiline 12-22 monoamine oxidase B Homo sapiens 117-136 29159774-1 2018 BACKGROUND AND OBJECTIVES: Rasagiline tablet is an oral MAO-B inhibitor applied in early or advanced Parkinson"s disease (PD). rasagiline 27-37 monoamine oxidase B Homo sapiens 56-61 29464559-3 2018 Currently, the treatment of Parkinson"s disease involves the use of selective MAO B inhibitors such as rasagiline and safinamide. rasagiline 103-113 monoamine oxidase B Homo sapiens 78-83 28577058-5 2017 Selegiline significantly increased Mao-B, which was suppressed by Mao-A knockdown with short interfering (si)RNA, whereas rasagiline less markedly increased Mao-B, which was not affected by Mao-A knockdown. rasagiline 122-132 monoamine oxidase B Homo sapiens 157-162 28577058-9 2017 Rasagiline increased BDNF and GDNF, which Mao-B and Mao-A knockdown inhibited. rasagiline 0-10 monoamine oxidase B Homo sapiens 42-47 28577058-10 2017 These results show that MAO-B might function as a repressor and MAO-A as a mediator in the constitutional expression of pro-survival genes, and that MAO-B and MAO-A might regulate different signal pathways for rasagiline and selegiline to induce neuroprotective genes. rasagiline 210-220 monoamine oxidase B Homo sapiens 24-29 28577058-10 2017 These results show that MAO-B might function as a repressor and MAO-A as a mediator in the constitutional expression of pro-survival genes, and that MAO-B and MAO-A might regulate different signal pathways for rasagiline and selegiline to induce neuroprotective genes. rasagiline 210-220 monoamine oxidase B Homo sapiens 149-154 27729794-1 2016 INTRODUCTION: Rasagiline is a selective, irreversible monoamine oxidase B inhibitor that ameliorates the symptoms of Parkinson"s disease (PD) by inhibiting striatal dopamine metabolism. rasagiline 14-24 monoamine oxidase B Homo sapiens 54-73 28550482-1 2017 Monoamine oxidase type B (MAO-B) inhibitors, such as selegiline and rasagiline, can be used as monotherapy or adjuvant therapy to levodopa in Parkinson"s disease (PD). rasagiline 68-78 monoamine oxidase B Homo sapiens 0-24 28550482-1 2017 Monoamine oxidase type B (MAO-B) inhibitors, such as selegiline and rasagiline, can be used as monotherapy or adjuvant therapy to levodopa in Parkinson"s disease (PD). rasagiline 68-78 monoamine oxidase B Homo sapiens 26-31 28148284-4 2017 Recently, her Stalevo had been changed to rasagiline (a monoamine oxidase B inhibitor). rasagiline 42-52 monoamine oxidase B Homo sapiens 56-75 30566307-9 2017 Rasagiline is a widely used MAO-B inhibitor in many countries. rasagiline 0-10 monoamine oxidase B Homo sapiens 28-33 27318273-2 2016 Based on this rational, a new class of cholinesterase (ChE)-monoamine oxidase (MAO) inhibitors were designed and synthesized by amalgamating the propargyl moiety of the irreversible selective MAO-B inhibitor, neuroprotective/neurorestorative anti-Parkinsonian drug, rasagiline, into the "N-methyl" position of the ChE inhibitor, anti-AD drug rivastigmine. rasagiline 266-276 monoamine oxidase B Homo sapiens 192-197 28293967-1 2017 OBJECTIVE: Rasagiline is a second-generation potent selective inhibitor of monoamine oxidase-B. rasagiline 11-21 monoamine oxidase B Homo sapiens 75-94 28299453-4 2017 We confirm with this design, that rasagiline and selegiline inhibit monoamine oxidase-B but not monoamine oxidase-A after single dosing. rasagiline 34-44 monoamine oxidase B Homo sapiens 68-87 28301816-8 2017 The reference drugs selegiline (IC50 = 0.040 muM) and rasagiline (IC50 = 0.066 muM) also displayed a significant inhibition against hMAO-B. rasagiline 54-64 monoamine oxidase B Homo sapiens 132-138 27089850-1 2016 Rasagiline is a monoamine oxidase type B inhibitor that possesses no amphetamine-like properties, and provides symptomatic relief in early and late stages of Parkinson"s disease (PD). rasagiline 0-10 monoamine oxidase B Homo sapiens 16-40 27060436-1 2016 Rasagiline is a selective, irreversible inhibitor of monoamine oxidase type-B (MAO-B) and has been used both as a monotherapy and in addition to levodopa in the treatment of Parkinson"s disease (PD). rasagiline 0-10 monoamine oxidase B Homo sapiens 53-77 27230855-2 2016 The MAO-B inhibitor rasagiline has shown neuroprotective effects in preclinical models of neurodegeneration. rasagiline 20-30 monoamine oxidase B Homo sapiens 4-9 27060436-1 2016 Rasagiline is a selective, irreversible inhibitor of monoamine oxidase type-B (MAO-B) and has been used both as a monotherapy and in addition to levodopa in the treatment of Parkinson"s disease (PD). rasagiline 0-10 monoamine oxidase B Homo sapiens 79-84 26897020-0 2016 Erratum to: Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. rasagiline 134-144 monoamine oxidase B Homo sapiens 60-79 28635937-0 2016 [A role of the MAO-B inhibitor rasagiline in treatment of Parkinson"s disease]. rasagiline 31-41 monoamine oxidase B Homo sapiens 15-20 25604428-3 2016 It has been suggested that the irreversible MAO-B inhibitors selegiline and rasagiline exert a neuroprotective effect in Parkinson"s and Alzheimer"s diseases. rasagiline 76-86 monoamine oxidase B Homo sapiens 44-49 25604428-5 2016 There is increasing evidence that MAO-A activity, but not that of MAO-B, is implicated in the pathophysiology of neurodegenerative disorders, but also in gene induction by MAO-B inhibitors; on the other hand, selegiline and rasagiline increase MAO-A mRNA, protein, and enzyme activity levels. rasagiline 224-234 monoamine oxidase B Homo sapiens 172-177 28635937-4 2016 Rasagiline (azilect), a new generation MAO-B inhibitor, helps to solve the problems at different stages of PD. rasagiline 0-10 monoamine oxidase B Homo sapiens 39-44 28635937-4 2016 Rasagiline (azilect), a new generation MAO-B inhibitor, helps to solve the problems at different stages of PD. rasagiline 12-19 monoamine oxidase B Homo sapiens 39-44 25322951-1 2014 Rasagiline (Azilect( )) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 79-98 25863936-1 2015 Rasagiline and selegiline, inhibitors of type B monoamine oxidase (MAO-B), protect neurons from cell death in cellular and animal models. rasagiline 0-10 monoamine oxidase B Homo sapiens 67-72 25368372-1 2015 OBJECTIVE: The current study examined the efficacy and safety of rasagiline, a selective MAO-B inhibitor, for the treatment of persistent negative symptoms. rasagiline 65-75 monoamine oxidase B Homo sapiens 89-94 25514361-1 2015 Rasagiline (N-propargyl-1-R-aminoindan) and selegiline (1-deprenyl) are MAO-B inhibitors which are used in the treatment of Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 72-77 26364897-1 2015 INTRODUCTION: Rasagiline is a potent, selective, irreversible Monoamine Oxidase-B (MAO-B) inhibitor, developed to prolong the action of dopamine in the brain. rasagiline 14-24 monoamine oxidase B Homo sapiens 62-81 26364897-1 2015 INTRODUCTION: Rasagiline is a potent, selective, irreversible Monoamine Oxidase-B (MAO-B) inhibitor, developed to prolong the action of dopamine in the brain. rasagiline 14-24 monoamine oxidase B Homo sapiens 83-88 25420207-3 2015 We report the effects of the addition of a monoamine oxidase B inhibitor, rasagiline, to antidepressant treatment in PD. rasagiline 74-84 monoamine oxidase B Homo sapiens 43-62 25314256-1 2014 BACKGROUND: The serotonin toxicity syndrome (STS) is a potential risk with concurrent use of the monoamine oxidase type-B inhibitor rasagiline and antidepressants. rasagiline 132-142 monoamine oxidase B Homo sapiens 97-121 25322951-1 2014 Rasagiline (Azilect( )) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 100-105 25322951-1 2014 Rasagiline (Azilect( )) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson"s disease. rasagiline 12-19 monoamine oxidase B Homo sapiens 79-98 25322951-1 2014 Rasagiline (Azilect( )) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson"s disease. rasagiline 12-19 monoamine oxidase B Homo sapiens 100-105 24447649-0 2014 Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson"s disease: a thorough QT/QTc study. rasagiline 18-28 monoamine oxidase B Homo sapiens 42-66 25196265-1 2014 INTRODUCTION: Oxidative stress reduction via monoamine oxidase-B (MAO-B) inhibition with rasagiline is under investigation to modify the course of Parkinson"s disease (PD) progression. rasagiline 89-99 monoamine oxidase B Homo sapiens 45-64 25196265-1 2014 INTRODUCTION: Oxidative stress reduction via monoamine oxidase-B (MAO-B) inhibition with rasagiline is under investigation to modify the course of Parkinson"s disease (PD) progression. rasagiline 89-99 monoamine oxidase B Homo sapiens 66-71 24769350-3 2014 In designing the compounds we focused on the structures of rasagiline and selegiline, two well known MAO-B inhibitors and proposed neuroprotective agents. rasagiline 59-69 monoamine oxidase B Homo sapiens 101-106 24055209-3 2014 Rasagiline is a second generation MAO-B I inducing moderate symptomatic and possibly disease modifying benefits with apparently good tolerability and safety profile in PD patients. rasagiline 0-10 monoamine oxidase B Homo sapiens 34-39 24447649-1 2014 AIMS: Rasagiline is a selective, irreversible monoamine oxidase type B inhibitor, developed for the treatment of Parkinson"s disease. rasagiline 6-16 monoamine oxidase B Homo sapiens 46-70 24190245-2 2013 The aim of this investigation was to determine if the MAO-B inhibitor rasagiline can improve olfaction in PD patients. rasagiline 70-80 monoamine oxidase B Homo sapiens 54-59 26000219-1 2014 Rasagiline is a monoamine oxidase type-B inhibitor used as monotherapy or in addition to levodopa in the treatment of Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 16-40 23735235-1 2013 Rasagiline (Azilect( )) is a selective and irreversible monoamine oxidase B inhibitor, which is well tolerated, safe, improves motor symptoms, and prevents motor complications in Parkinson"s disease (PD). rasagiline 0-10 monoamine oxidase B Homo sapiens 56-75 24012376-1 2013 The objective of this study was to synthesize and evaluate a novel fluorine-18 labeled deuterium substituted analogue of rasagiline (9, [(18)F]fluororasagiline-D2) as a potential PET radioligand for studies of monoamine oxidase B (MAO-B). rasagiline 121-131 monoamine oxidase B Homo sapiens 210-229 24012376-1 2013 The objective of this study was to synthesize and evaluate a novel fluorine-18 labeled deuterium substituted analogue of rasagiline (9, [(18)F]fluororasagiline-D2) as a potential PET radioligand for studies of monoamine oxidase B (MAO-B). rasagiline 121-131 monoamine oxidase B Homo sapiens 231-236 23735235-1 2013 Rasagiline (Azilect( )) is a selective and irreversible monoamine oxidase B inhibitor, which is well tolerated, safe, improves motor symptoms, and prevents motor complications in Parkinson"s disease (PD). rasagiline 12-19 monoamine oxidase B Homo sapiens 56-75 23634791-1 2013 INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B). rasagiline 14-24 monoamine oxidase B Homo sapiens 86-105 23634791-1 2013 INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B). rasagiline 14-24 monoamine oxidase B Homo sapiens 107-112 23634791-1 2013 INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B). rasagiline 26-33 monoamine oxidase B Homo sapiens 86-105 23634791-1 2013 INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B). rasagiline 26-33 monoamine oxidase B Homo sapiens 107-112 23634791-1 2013 INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B). rasagiline 35-43 monoamine oxidase B Homo sapiens 86-105 23634791-1 2013 INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B). rasagiline 35-43 monoamine oxidase B Homo sapiens 107-112 23634791-11 2013 In conclusion, rasagiline is a well-tolerated MAO-B inhibitor that may help to achieve the desired level of clinical benefit in Parkinson"s disease. rasagiline 15-25 monoamine oxidase B Homo sapiens 46-51 23410524-4 2013 l-Deprenyl and rasagiline, both selective MAO-B inhibitors, are used in the management of Parkinson"s disease, but these drugs may be useful in the treatment of other neurodegenerative disorders given that they demonstrate neuroprotective/neurorescue properties in a wide variety of models in vitro and in vivo. rasagiline 15-25 monoamine oxidase B Homo sapiens 42-47 23176073-1 2013 OBJECTIVE: Rasagiline is a second-generation, irreversible MAO-B inhibitor (MAOB-I) previously shown to be efficacious and well-tolerated compared to placebo in the treatment of early Parkinson"s disease (PD). rasagiline 11-21 monoamine oxidase B Homo sapiens 59-64 23410161-6 2013 The design strategy for yet another agent, ladostigil, employed the amalgamation of active chemical moieties of the AChE inhibitor rivastigmine, and the monoamine oxidase-B (MAO-B) inhibitor rasagiline, leading to a single compound that targets both enzymes simultaneously. rasagiline 191-201 monoamine oxidase B Homo sapiens 153-172 23410161-6 2013 The design strategy for yet another agent, ladostigil, employed the amalgamation of active chemical moieties of the AChE inhibitor rivastigmine, and the monoamine oxidase-B (MAO-B) inhibitor rasagiline, leading to a single compound that targets both enzymes simultaneously. rasagiline 191-201 monoamine oxidase B Homo sapiens 174-179 23242744-7 2013 The MAO-B inhibition activities of the candidates were compared with the properties of rasagiline which is known to be a selective inhibitor of MAO-B. rasagiline 87-97 monoamine oxidase B Homo sapiens 144-149 22968599-2 2013 MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neuronal cells by direct intervention in mitochondrial death signaling and induction of pro-survival Bcl-2 and neurotrophic factors. rasagiline 18-28 monoamine oxidase B Homo sapiens 0-5 22954444-1 2012 The objective was to investigate the anodal iontophoresis of the MAO-B inhibitors rasagiline (RAS) and selegiline (SEL) across porcine and human skin in vitro. rasagiline 82-92 monoamine oxidase B Homo sapiens 65-70 22954444-1 2012 The objective was to investigate the anodal iontophoresis of the MAO-B inhibitors rasagiline (RAS) and selegiline (SEL) across porcine and human skin in vitro. rasagiline 94-97 monoamine oxidase B Homo sapiens 65-70 21628600-0 2012 The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? rasagiline 39-49 monoamine oxidase B Homo sapiens 4-28 23346517-5 2012 Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor that has recently been approved by the Food and Drug Administration for treatment of Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 48-72 23346517-5 2012 Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor that has recently been approved by the Food and Drug Administration for treatment of Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 74-79 22691758-3 2012 In this review, we focus on recent studies with monoamine oxidase type B inhibitors (selegiline and rasagiline), coenzyme Q10, creatine, and exercise in early Parkinson"s disease. rasagiline 100-110 monoamine oxidase B Homo sapiens 48-72 22436387-1 2012 The aim of this study was to synthesize and evaluate a novel fluorine-18 labeled analogue of rasagiline (6) as a PET radioligand for monoamine oxidase B (MAO-B). rasagiline 93-103 monoamine oxidase B Homo sapiens 133-152 22436387-1 2012 The aim of this study was to synthesize and evaluate a novel fluorine-18 labeled analogue of rasagiline (6) as a PET radioligand for monoamine oxidase B (MAO-B). rasagiline 93-103 monoamine oxidase B Homo sapiens 154-159 22436387-7 2012 Blocking experiments with pirlindole (MAO-A), L-deprenyl and rasagiline (MAO-B) were conducted to demonstrate the specificity of the binding. rasagiline 61-71 monoamine oxidase B Homo sapiens 73-78 21628600-1 2012 Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa. rasagiline 0-10 monoamine oxidase B Homo sapiens 30-54 21628600-1 2012 Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa. rasagiline 0-10 monoamine oxidase B Homo sapiens 56-61 21628600-3 2012 Tyramine challenge studies, conducted to characterize rasagiline selectivity for the MAO-B enzyme and tyramine sensitivity, demonstrate that rasagiline, when used at the recommended dose, is selective for MAO-B and is not associated with heightened tyramine sensitivity. rasagiline 54-64 monoamine oxidase B Homo sapiens 85-90 21628600-3 2012 Tyramine challenge studies, conducted to characterize rasagiline selectivity for the MAO-B enzyme and tyramine sensitivity, demonstrate that rasagiline, when used at the recommended dose, is selective for MAO-B and is not associated with heightened tyramine sensitivity. rasagiline 141-151 monoamine oxidase B Homo sapiens 85-90 21628600-3 2012 Tyramine challenge studies, conducted to characterize rasagiline selectivity for the MAO-B enzyme and tyramine sensitivity, demonstrate that rasagiline, when used at the recommended dose, is selective for MAO-B and is not associated with heightened tyramine sensitivity. rasagiline 141-151 monoamine oxidase B Homo sapiens 205-210 21628600-6 2012 In addition, because rasagiline has been demonstrated to be selective for MAO-B at the approved dose of up to 1 mg/d, contraindications regarding concomitant use with sympathomimetic amines, use of sympathomimetic vasopressors in conjunction with general or local anesthesia, and use in patients with pheochromocytoma also were removed. rasagiline 21-31 monoamine oxidase B Homo sapiens 74-79 23030609-0 2012 QSAR and molecular docking techniques for the discovery of potent monoamine oxidase B inhibitors: computer-aided generation of new rasagiline bioisosteres. rasagiline 131-141 monoamine oxidase B Homo sapiens 66-85 22065207-1 2012 Rasagiline and (-)deprenyl (selegiline), irreversible type B monoamine oxidase (MAO-B) inhibitors, protect neuronal cells through gene induction of pro-survival Bcl-2 and neurotrophic factors in the cellular models of neurodegenerative disorders. rasagiline 0-10 monoamine oxidase B Homo sapiens 80-85 22065207-5 2012 MAO-B overexpression inhibited Bcl-2 induction by rasagiline and befloxatone, but did not affect that by (-)deprenyl, suggesting the different mechanisms behind Bcl-2 gene induction by these MAO-B inhibitors. rasagiline 50-60 monoamine oxidase B Homo sapiens 0-5 22439669-1 2012 Rasagiline (Azilect ), a selective, irreversible, monoamine oxidase-B inhibitor, is available in the EU, the US and in several other countries worldwide, including Canada and Israel. rasagiline 0-10 monoamine oxidase B Homo sapiens 50-69 22439669-1 2012 Rasagiline (Azilect ), a selective, irreversible, monoamine oxidase-B inhibitor, is available in the EU, the US and in several other countries worldwide, including Canada and Israel. rasagiline 12-19 monoamine oxidase B Homo sapiens 50-69 21819487-1 2012 BACKGROUND: Rasagiline, an MAO-B inhibitor, is indicated for the treatment of Parkinson"s disease (PD). rasagiline 12-22 monoamine oxidase B Homo sapiens 27-32 23231395-4 2012 On the other hand, deprenyl and rasagiline, selective MAO-B inhibitors, have been proved to protect neuronal cells in cellular and animal models of neurodegeneration. rasagiline 32-42 monoamine oxidase B Homo sapiens 54-59 23030609-6 2012 We also give a brief overview about one of the most potent MAO-B inhibitor drugs: rasagiline. rasagiline 82-92 monoamine oxidase B Homo sapiens 59-64 23030609-8 2012 By realizing a careful inspection of the meaning of the variables in the QSAR-ANN model, new rasagiline bioisosteres were suggested as possible potent MAO-B inhibitors. rasagiline 93-103 monoamine oxidase B Homo sapiens 151-156 21953831-5 2011 Monoamine oxidase B (MAO-B) located in the outer mitochondrial membrane controls dopamine metabolism in early PD, and this is the likely location for the symptomatic action of rasagiline. rasagiline 176-186 monoamine oxidase B Homo sapiens 0-19 22045282-1 2011 OBJECTIVE: Rasagiline, a monoamine oxidase type B inhibitor, is indicated for both the initial treatment of Parkinson disease (PD) and as adjunctive (add-on) treatment for patients already taking dopaminergic therapy. rasagiline 11-21 monoamine oxidase B Homo sapiens 25-49 22133327-4 2011 Two MAO-B inhibitors, selegiline and rasagiline, are currently licensed in Europe and North America for the symptomatic improvement of early Parkinson"s disease and to reduce off-time in patients with more advanced Parkinson"s disease and motor fluctuations related to levodopa. rasagiline 37-47 monoamine oxidase B Homo sapiens 4-9 21953831-5 2011 Monoamine oxidase B (MAO-B) located in the outer mitochondrial membrane controls dopamine metabolism in early PD, and this is the likely location for the symptomatic action of rasagiline. rasagiline 176-186 monoamine oxidase B Homo sapiens 21-26 21953831-8 2011 Thus, the functional neuroprotective actions of rasagiline may not be dependent on MAO-B inhibition, but rather may involve actions of the propargylamine moiety and the aminoindan metabolite. rasagiline 48-58 monoamine oxidase B Homo sapiens 83-88 21500280-2 2011 Rasagiline is a selective monoamine oxidase type-B inhibitor that enhances central dopaminergic transmission. rasagiline 0-10 monoamine oxidase B Homo sapiens 26-50 22087552-8 2011 It appears that early treatment with the MAO-B inhibitor rasagiline (1 mg), as compared with late treatment, delays the onset of worsened UPDRS score, especially the nonmotor activities of daily living subscore. rasagiline 57-67 monoamine oxidase B Homo sapiens 41-46 21939547-4 2011 DISCUSSION: In multiple studies, MAO-B inhibitors, such as selegiline and rasagiline, have shown to provide mild symptomatic effects, delay the need for levodopa, and to reduce the incidence of motor fluctuations. rasagiline 74-84 monoamine oxidase B Homo sapiens 33-38 21500280-13 2011 The monoamine oxidase type-B inhibitor rasagiline may exert beneficial effects on certain aspects of attention and executive functions in nondemented patients with Parkinson"s disease with cognitive impairment. rasagiline 39-49 monoamine oxidase B Homo sapiens 4-28 22110357-4 2011 For the treatment of akinesia and motor fluctuations selective irreversible MAO-B inhibitors selegiline and rasagiline are recommended. rasagiline 108-118 monoamine oxidase B Homo sapiens 76-81 21812497-12 2011 Of the three delayed-start design clinical trials, two have investigated early versus later start of rasagiline, a specific irreversible monoamine oxidase B inhibitor. rasagiline 101-111 monoamine oxidase B Homo sapiens 137-156 21626552-5 2011 Novel dopamine agonists (pramipexole, ropinirole, rotigotine), catecholmethyltransferase inhibitors (entacapone), and monoamine oxidase B inhibitors (rasagiline) have also been developed to provide more continuous oral delivery of dopaminergic stimulation in order to improve motor outcomes. rasagiline 150-160 monoamine oxidase B Homo sapiens 118-137 21971007-2 2011 The MAO-B inhibitor rasagiline has neuroprotective effects in animal models, mediated partly by its antiapoptotic activity. rasagiline 20-30 monoamine oxidase B Homo sapiens 4-9 21971006-2 2011 Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible MAO-B inhibitor in the treatment of Parkinson"s disease (PD). rasagiline 0-10 monoamine oxidase B Homo sapiens 81-86 21360301-3 2011 Although Moussa Youdim succeeded in exploring the novel anti-Parkinsonian, selective MAO-B inhibitor drug, rasagiline (Azilect, Teva Pharmaceutical Co.), he did not stop searching for superior therapeutic approaches for neurodegenerative disorders. rasagiline 107-117 monoamine oxidase B Homo sapiens 85-90 21423589-4 2011 This review focuses on rasagiline and selegiline, two medications that belong to a class of antiparkinsonian drugs called monoamine oxidase B (MAO-B) inhibitors. rasagiline 23-33 monoamine oxidase B Homo sapiens 122-141 21423589-4 2011 This review focuses on rasagiline and selegiline, two medications that belong to a class of antiparkinsonian drugs called monoamine oxidase B (MAO-B) inhibitors. rasagiline 23-33 monoamine oxidase B Homo sapiens 143-148 21075154-10 2011 Deprenyl itself as well as the MAO-B antagonist rasagiline did effectively block the binding of the radioligand, whereas the MAO-A antagonist pirlindole did not affect it. rasagiline 48-58 monoamine oxidase B Homo sapiens 31-36 21947069-1 2011 The features of the new selective MAO-B inhibitor razagiline (azilect) are reviewed against the background of latest advances in the field of treatment of Parkinson"s disease (PD). rasagiline 62-69 monoamine oxidase B Homo sapiens 34-39 20624440-1 2010 Rasagiline is a propargylamine and irreversible monoamine oxidase (MAO) B inhibitor used for the treatment of Parkinson"s disease (PD). rasagiline 0-10 monoamine oxidase B Homo sapiens 48-73 20445015-0 2010 Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. rasagiline 126-136 monoamine oxidase B Homo sapiens 83-107 20445015-0 2010 Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. rasagiline 126-136 monoamine oxidase B Homo sapiens 109-114 20445015-1 2010 Rasagiline is a selective, monoamine oxidase (MAO)-B inhibitor indicated for treatment of Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 27-52 20445015-9 2010 Results demonstrate that rasagiline selectively inhibits MAO-B and is not associated with increased tyramine sensitivity at the indicated dose (1 mg/d). rasagiline 25-35 monoamine oxidase B Homo sapiens 57-62 20600573-0 2010 Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. rasagiline 0-10 monoamine oxidase B Homo sapiens 38-57 20600573-1 2010 Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. rasagiline 0-10 monoamine oxidase B Homo sapiens 81-106 20600573-3 2010 Its S-isomer, TVP1022 is thousand times less potent as an MAO-B inhibitor. rasagiline 14-21 monoamine oxidase B Homo sapiens 58-63 20600573-4 2010 However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins. rasagiline 186-196 monoamine oxidase B Homo sapiens 230-235 20979033-4 2010 DEVELOPMENT: Rasagiline is a monoamine oxidase-B inhibitor whose dopaminergic stimulation has proved to be effective in monotherapy or in combined therapy for improving the motor symptoms in patients with PD in the initial and advanced phases. rasagiline 13-23 monoamine oxidase B Homo sapiens 29-48 19526291-0 2009 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. rasagiline 116-126 monoamine oxidase B Homo sapiens 41-60 20236308-1 2010 BACKGROUND: The MAO-B inhibitor rasagiline is indicated for the treatment of idiopathic Parkinson"s disease (PD), and its use is supported by evidence from large-scale, controlled clinical studies. rasagiline 32-42 monoamine oxidase B Homo sapiens 16-21 20022592-10 2010 Knockdown expression of GAPDH or treatment with MAO B inhibitors selegiline (deprenyl) and rasagiline (Azilect) can block this cascade. rasagiline 91-101 monoamine oxidase B Homo sapiens 48-53 20022592-10 2010 Knockdown expression of GAPDH or treatment with MAO B inhibitors selegiline (deprenyl) and rasagiline (Azilect) can block this cascade. rasagiline 103-110 monoamine oxidase B Homo sapiens 48-53 20195940-3 2010 The MAO B inhibitors selegiline and rasagiline are in use for PD pharmacotherapy; for rasagiline, studies have demonstrated a possible disease-modifying effect. rasagiline 36-46 monoamine oxidase B Homo sapiens 4-9 21389939-1 2010 An open observational 3-month study of efficacy and safety of selective MAO B inhibitor rasagiline (AZIlect) in advanced Parkinson"s disease (PD) patients with motor fluctuations on the long-term levodopa therapy (the "AZIMUT" study) has been conducted. rasagiline 88-98 monoamine oxidase B Homo sapiens 72-77 21389939-1 2010 An open observational 3-month study of efficacy and safety of selective MAO B inhibitor rasagiline (AZIlect) in advanced Parkinson"s disease (PD) patients with motor fluctuations on the long-term levodopa therapy (the "AZIMUT" study) has been conducted. rasagiline 100-107 monoamine oxidase B Homo sapiens 72-77 19673610-5 2009 Rasagiline-related MAOB-Is prevent mitochondrial permeability transition induced by various insults and activation of subsequent apoptotic cascades: cytochrome c release, casapase activation, and condensation and fragmentation of nuclear DNA. rasagiline 0-10 monoamine oxidase B Homo sapiens 19-23 23908775-0 2010 Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson"s Disease with Neuroprotective Potential. rasagiline 16-26 monoamine oxidase B Homo sapiens 34-39 23908775-1 2010 Rasagiline (Azilect) is a highly selective and potent propargylamine inhibitor of monoamine oxidase (MAO) type B. rasagiline 0-10 monoamine oxidase B Homo sapiens 82-112 23908775-1 2010 Rasagiline (Azilect) is a highly selective and potent propargylamine inhibitor of monoamine oxidase (MAO) type B. rasagiline 12-19 monoamine oxidase B Homo sapiens 82-112 20517484-3 2010 Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. rasagiline 0-10 monoamine oxidase B Homo sapiens 48-72 20517484-3 2010 Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. rasagiline 0-10 monoamine oxidase B Homo sapiens 74-79 20517484-4 2010 Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. rasagiline 0-10 monoamine oxidase B Homo sapiens 20-25 20002521-1 2010 The anti-parkinsonian drug, rasagiline [N-propargyl-1-(R)-aminoindan; Azilect(R)], is a secondary cyclic benzylamine and indane derivative, which provides irreversible, potent monoamine oxidase-B (MAO-B) inhibition and possesses neuroprotective and neurorestorative activities. rasagiline 28-38 monoamine oxidase B Homo sapiens 176-195 20002521-1 2010 The anti-parkinsonian drug, rasagiline [N-propargyl-1-(R)-aminoindan; Azilect(R)], is a secondary cyclic benzylamine and indane derivative, which provides irreversible, potent monoamine oxidase-B (MAO-B) inhibition and possesses neuroprotective and neurorestorative activities. rasagiline 28-38 monoamine oxidase B Homo sapiens 197-202 20002521-3 2010 Rasagiline is primarily metabolized by hepatic cytochrome P-450 to form its major metabolite, 1-(R)-aminoindan, a non-amphetamine, weak reversible MAO-B inhibitor compound. rasagiline 0-10 monoamine oxidase B Homo sapiens 147-152 20977789-1 2010 Rasagiline is a MAO-B inhibitor that is currently registered for the symptomatic treatment of Parkinson disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 16-21 20197647-1 2010 BACKGROUND: The anti-Parkinson monoamine oxidase B inhibitor rasagiline appears to be the first neuroprotective disease-modifying therapy in early-stage Parkinson"s disease (PD). rasagiline 61-71 monoamine oxidase B Homo sapiens 31-50 19733607-5 2009 The MAO-A-dependent catecholamine metabolite DHPG levels did not change significantly during the study suggesting that rasagiline"s MAO-B selectivity was preserved. rasagiline 119-129 monoamine oxidase B Homo sapiens 132-137 19753135-1 2009 Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. rasagiline 0-10 monoamine oxidase B Homo sapiens 59-83 19753135-1 2009 Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. rasagiline 0-10 monoamine oxidase B Homo sapiens 85-90 19526291-6 2009 In contrast, the MAO B inhibitors rasagiline and selegiline (0.25 nM) and the rasagiline metabolite, 1-R-aminoindan (1 muM) decreases the ethanol-induced MAO B, prevents nuclear translocation of GAPDH and reduces cell death. rasagiline 34-44 monoamine oxidase B Homo sapiens 17-22 19526291-6 2009 In contrast, the MAO B inhibitors rasagiline and selegiline (0.25 nM) and the rasagiline metabolite, 1-R-aminoindan (1 muM) decreases the ethanol-induced MAO B, prevents nuclear translocation of GAPDH and reduces cell death. rasagiline 34-44 monoamine oxidase B Homo sapiens 154-159 19526291-6 2009 In contrast, the MAO B inhibitors rasagiline and selegiline (0.25 nM) and the rasagiline metabolite, 1-R-aminoindan (1 muM) decreases the ethanol-induced MAO B, prevents nuclear translocation of GAPDH and reduces cell death. rasagiline 78-88 monoamine oxidase B Homo sapiens 154-159 19526291-10 2009 Thus, the neuroprotective effects of rasagiline or 1-R-aminoindan on ethanol-induced cell death mediated by a novel GAPDH-MAO B pathway may provide a new insight in the treatment of neurobiological diseases including alcohol-use disorders. rasagiline 37-47 monoamine oxidase B Homo sapiens 122-127 18937611-1 2008 BACKGROUND: The role of monoamine oxidase type B inhibitors in the treatment of Parkinson"s disease has expanded with the new monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets. rasagiline 156-166 monoamine oxidase B Homo sapiens 24-48 19110207-2 2009 Ladostigil combines, in a single molecule, the neuroprotective/neurorestorative effects of the novel anti-Parkinsonian drug and selective monoamine oxidase (MAO)-B inhibitor, rasagiline (Azilect, Teva Pharmaceutical Co.) with the cholinesterase (ChE) inhibitory activity of rivastigmine. rasagiline 175-185 monoamine oxidase B Homo sapiens 138-163 19384601-10 2009 Rasagiline exhibited highest inhibition on MAO B enzymatic activity and prevention on DNA damage as compared to selegiline and 1-R-aminoindan. rasagiline 0-10 monoamine oxidase B Homo sapiens 43-48 18952510-1 2008 Rasagiline is a highly potent, selective and irreversible second-generation monoamine oxidase inhibitor with selectivity for type B of the enzyme (MAO-B). rasagiline 0-10 monoamine oxidase B Homo sapiens 147-152 18937611-9 2008 The recently released monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets, have potential advantages over conventional oral selegiline. rasagiline 52-62 monoamine oxidase B Homo sapiens 22-41 18678789-0 2008 Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. rasagiline 80-90 monoamine oxidase B Homo sapiens 50-69 18833504-2 2008 Rasagiline (Azilect) is a potent, highly selective and irreversible inhibitor of monoamine oxidase type B of the second generation. rasagiline 0-10 monoamine oxidase B Homo sapiens 81-105 18833504-2 2008 Rasagiline (Azilect) is a potent, highly selective and irreversible inhibitor of monoamine oxidase type B of the second generation. rasagiline 12-19 monoamine oxidase B Homo sapiens 81-105 16717254-7 2006 Rasagiline is another MAO-B inhibitor that contains a propargyl ring and has protective effects in laboratory models. rasagiline 0-10 monoamine oxidase B Homo sapiens 22-27 18067186-3 2008 Treatment with the new irreversible monoamine oxidase B inhibitor rasagiline at standard doses resulted in a rapid, dramatic, and sustained improvement of the frequency and duration of FOG episodes. rasagiline 66-76 monoamine oxidase B Homo sapiens 36-55 18041937-3 2007 The two available MAO-B inhibitors approved for use in the United States, rasagiline and selegiline, each provide symptomatic relief as monotherapy and as adjunctive therapy, and have shown potential disease-modifying effects in experimental models and clinical studies. rasagiline 74-84 monoamine oxidase B Homo sapiens 18-23 18035186-2 2007 Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson"s disease (PD). rasagiline 0-10 monoamine oxidase B Homo sapiens 142-147 18035186-8 2007 Based on the results from those studies, we concluded that rasagiline PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited MAO-B. rasagiline 59-69 monoamine oxidase B Homo sapiens 216-221 18488080-0 2007 Rasagiline - a novel MAO B inhibitor in Parkinson"s disease therapy. rasagiline 0-10 monoamine oxidase B Homo sapiens 21-26 18488080-3 2007 Recently, a novel selective and irreversible MAO B propargylamine inhibitor rasagiline (N-propargyl-1-R-aminoindan, Azilect((R))) was approved for PD therapy. rasagiline 76-86 monoamine oxidase B Homo sapiens 45-50 18488080-3 2007 Recently, a novel selective and irreversible MAO B propargylamine inhibitor rasagiline (N-propargyl-1-R-aminoindan, Azilect((R))) was approved for PD therapy. rasagiline 116-123 monoamine oxidase B Homo sapiens 45-50 16935943-2 2006 Ladostigil combines the neuroprotective effects of the antiparkinson drug rasagiline, a selective monoamine oxidase (MAO)-B inhibitor, with the cholinesterase (ChE) inhibitory activity of rivastigmine in a single molecule, as a potential treatment for Alzheimer"s disease (AD) and Lewy Body disease. rasagiline 74-84 monoamine oxidase B Homo sapiens 98-123 16856145-0 2006 Effects of tyramine administration in Parkinson"s disease patients treated with selective MAO-B inhibitor rasagiline. rasagiline 106-116 monoamine oxidase B Homo sapiens 90-95 16856145-1 2006 Rasagiline is a novel, potent, and selective MAO-B inhibitor shown to be effective for Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 45-50 20104716-4 2006 For young patients, dopamine-agonists and, indeed, once again increasingly MAO-B inhibitors, such as rasagiline, are mainly used for therapy. rasagiline 101-111 monoamine oxidase B Homo sapiens 75-80 18307054-1 2008 Rasagiline is a selective and irreversible monoamine oxidase-B inhibitor. rasagiline 0-10 monoamine oxidase B Homo sapiens 43-62 18072817-1 2008 Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). rasagiline 0-10 monoamine oxidase B Homo sapiens 88-112 18072817-1 2008 Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). rasagiline 0-10 monoamine oxidase B Homo sapiens 114-119 18072817-1 2008 Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). rasagiline 12-19 monoamine oxidase B Homo sapiens 88-112 18072817-1 2008 Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). rasagiline 12-19 monoamine oxidase B Homo sapiens 114-119 18668620-8 2008 MAO-B inhibitors (selegiline and rasagiline) can decrease FOG frequency or severity, but its clinical significance is still unknown. rasagiline 33-43 monoamine oxidase B Homo sapiens 0-5 19004128-0 2008 [The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson"s disease]. rasagiline 34-44 monoamine oxidase B Homo sapiens 18-23 17635668-1 2007 The anti-Parkinson, selective irreversible monoamine oxidase B inhibitor drug, rasagiline (Azilect), recently approved by the US Food and Drug Administration, has been shown to possess neuroprotective-neurorescue activities in in vitro and in vivo models. rasagiline 79-89 monoamine oxidase B Homo sapiens 43-62 17635668-1 2007 The anti-Parkinson, selective irreversible monoamine oxidase B inhibitor drug, rasagiline (Azilect), recently approved by the US Food and Drug Administration, has been shown to possess neuroprotective-neurorescue activities in in vitro and in vivo models. rasagiline 91-98 monoamine oxidase B Homo sapiens 43-62 17347320-2 2007 It was postulated that certain carbamate esters would inhibit AChE and BChE with the concomitant release in the brain of the OH-derivatives of rasagiline or selegiline that can serve as inhibitors of MAO-B and as antioxidants. rasagiline 143-153 monoamine oxidase B Homo sapiens 200-205 17545750-3 2007 Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, for the symptomatic treatment of Parkinson disease (PD). rasagiline 66-76 monoamine oxidase B Homo sapiens 48-53 17545750-7 2007 Rasagiline is a selective, second-generation, irreversible MAO-B inhibitor, with at least 5 times the potency of selegiline in vitro and in animal models. rasagiline 0-10 monoamine oxidase B Homo sapiens 59-64 17495756-4 2007 Although no medication has been proven to slow the progression of Parkinson disease, preclinical studies have demonstrated neuroprotective effects of MAO-B inhibitors, and a recent study of rasagiline found that PD patients treated with rasagiline for 12 months experienced less progression of symptoms than patients treated with placebo for 6 months followed by rasagiline for 6 months. rasagiline 237-247 monoamine oxidase B Homo sapiens 150-155 17495756-4 2007 Although no medication has been proven to slow the progression of Parkinson disease, preclinical studies have demonstrated neuroprotective effects of MAO-B inhibitors, and a recent study of rasagiline found that PD patients treated with rasagiline for 12 months experienced less progression of symptoms than patients treated with placebo for 6 months followed by rasagiline for 6 months. rasagiline 237-247 monoamine oxidase B Homo sapiens 150-155 17630819-5 2007 Agents that block MAO-B, such as rasagiline and selegiline, are used as both initial and adjunctive therapy in patients with Parkinson"s disease. rasagiline 33-43 monoamine oxidase B Homo sapiens 18-23 17683172-1 2007 Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). rasagiline 0-10 monoamine oxidase B Homo sapiens 88-112 17683172-1 2007 Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). rasagiline 0-10 monoamine oxidase B Homo sapiens 114-119 17683172-1 2007 Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). rasagiline 12-19 monoamine oxidase B Homo sapiens 88-112 17683172-1 2007 Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). rasagiline 12-19 monoamine oxidase B Homo sapiens 114-119 17702535-10 2007 Rasagiline is a new, selective, second-generation MAO-B inhibitor that is chemically and metabolically distinct from selegiline. rasagiline 0-10 monoamine oxidase B Homo sapiens 50-55 17055733-1 2007 The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities, involving the induction of brain-derived- and glial cell line-derived neurotrophic factors (BDNF, GDNF). rasagiline 55-65 monoamine oxidase B Homo sapiens 19-44 17055733-1 2007 The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities, involving the induction of brain-derived- and glial cell line-derived neurotrophic factors (BDNF, GDNF). rasagiline 67-74 monoamine oxidase B Homo sapiens 19-44 18267281-5 2007 MAO-B inhibitors rasagiline or selegiline can be also added. rasagiline 17-27 monoamine oxidase B Homo sapiens 0-5 17296539-18 2006 In addition, bifunctional molecules combining selective MAO-B inhibition (based on the active moiety of rasagiline) with acetylcholinesterase inhibition or iron chelation may eventually be useful in Alzheimer"s disease. rasagiline 104-114 monoamine oxidase B Homo sapiens 56-61 16828804-2 2006 Rasagiline (N-propargyl-1(R)-aminoindan) mesylate is a novel, second-generation, selective, irreversible monoamine oxidase type B inhibitor, demonstrated in monotherapy and adjunctive trials to be effective for PD with excellent tolerability. rasagiline 0-10 monoamine oxidase B Homo sapiens 105-129 16675649-0 2006 Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 32-56 16675649-2 2006 SUMMARY: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B). rasagiline 9-19 monoamine oxidase B Homo sapiens 106-130 16675649-2 2006 SUMMARY: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B). rasagiline 9-19 monoamine oxidase B Homo sapiens 132-137 16675649-3 2006 Rasagiline demonstrates complete and selective inhibition of MAO-B and is at least five times more potent than selegiline. rasagiline 0-10 monoamine oxidase B Homo sapiens 61-66 16675649-12 2006 CONCLUSION: Rasagiline is an investigational selective and irreversible inhibitor of MAO-B that has demonstrated efficacy and safety for the treatment of PD. rasagiline 12-22 monoamine oxidase B Homo sapiens 85-90 16717255-1 2006 Rasagiline (N-propargyl-1 (R)-aminoindan) is a selective, potent irreversible inhibitor of MAO-B that possesses neuroprotective and anti-apoptotic properties in a variety of in vitro and in vivo animal models relevant to Parkinson"s disease (PD). rasagiline 0-10 monoamine oxidase B Homo sapiens 91-96 16450340-2 2006 Rasagiline, a potent, second-generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early PD. rasagiline 0-10 monoamine oxidase B Homo sapiens 65-84 16425668-4 2006 The methyl-esterified form of L-DOPA (melevodopa) and the monoamine oxidase type B inhibitor rasagiline have both been launched. rasagiline 93-103 monoamine oxidase B Homo sapiens 58-82 16451296-4 2006 Rasagiline is a novel, second-generation, irreversible, selective monoamine oxidase type B inhibitor that is indicated for the treatment of idiopathic PD, either as initial monotherapy or as adjunct therapy (with levodopa) for patients experiencing end-of-dose motor fluctuations. rasagiline 0-10 monoamine oxidase B Homo sapiens 66-90 17017568-1 2006 Our recent studies aimed to elucidate the molecular and biochemical mechanism of actions of the novel anti-Parkinson"s drug, rasagiline, an irreversible and selective monoamine oxidase (MAO)-B inhibitor and its propargyl moiety, propargylamine. rasagiline 125-135 monoamine oxidase B Homo sapiens 167-192 17447416-7 2006 MAO B inhibitors such as L-(-)-deprenyl (selegiline) and rasagiline are effective for the treatment of PD. rasagiline 57-67 monoamine oxidase B Homo sapiens 0-5 16366596-2 2005 Rasagiline is an irreversible, MAO B-selective inhibitor that has been approved as a novel anti-Parkinson"s drug. rasagiline 0-10 monoamine oxidase B Homo sapiens 31-36 16366596-3 2005 In this study, we investigate the inhibition of recombinant human MAO A and MAO B by several rasagiline analogues. rasagiline 93-103 monoamine oxidase B Homo sapiens 76-81 16366596-6 2005 The 1.7 A crystal structure of MAO B in complex with 4-(N-methyl-N-ethyl-carbamoyloxy)-N-methyl-N-propargyl-1(R)-aminoindan shows that the binding mode is similar to that of rasagiline with the carbamate moiety occupying the entrance cavity space. rasagiline 174-184 monoamine oxidase B Homo sapiens 31-36 16366596-7 2005 1(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B. rasagiline 48-58 monoamine oxidase B Homo sapiens 112-117 16366596-8 2005 The crystal structure of N-methyl-1(R)-aminoindan bound to MAO B shows that its aminoindan ring adopts a different orientation compared to that of rasagiline. rasagiline 147-157 monoamine oxidase B Homo sapiens 59-64 16197359-2 2005 Rasagiline is a monoamine oxidase-B inhibitor that has demonstrated efficacy against the cardinal symptoms of Parkinson"s disease when used as monotherapy in early Parkinson"s disease, and as an adjunct to levodopa in advanced disease stages. rasagiline 0-10 monoamine oxidase B Homo sapiens 16-35 16274338-8 2005 Clinical data suggest, in addition, a disease-modifying effect of rasagiline that may correlate with neuroprotective activity of monoamine oxidase-B inhibitors in animal models of Parkinson"s disease. rasagiline 66-76 monoamine oxidase B Homo sapiens 129-148 16204711-0 2005 In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. rasagiline 62-72 monoamine oxidase B Homo sapiens 29-48 16204711-6 2005 The areas of high uptake were absent from scan 2, on which activity throughout the brain was comparable to that in white matter, presumably because of blocking of MAO-B binding sites by rasagiline. rasagiline 186-196 monoamine oxidase B Homo sapiens 163-168 16204711-8 2005 CONCLUSION: (11)C-l-deprenyl PET showed binding of rasagiline to MAO-B, confirming blocking of MAO-B sites after 10 d of treatment with 1 mg of rasagiline per day, with immediate post-rasagiline treatment tracer uptake and metabolism in the basal ganglia compatible only with nonspecific binding. rasagiline 51-61 monoamine oxidase B Homo sapiens 65-70 16204711-8 2005 CONCLUSION: (11)C-l-deprenyl PET showed binding of rasagiline to MAO-B, confirming blocking of MAO-B sites after 10 d of treatment with 1 mg of rasagiline per day, with immediate post-rasagiline treatment tracer uptake and metabolism in the basal ganglia compatible only with nonspecific binding. rasagiline 144-154 monoamine oxidase B Homo sapiens 95-100 16204711-8 2005 CONCLUSION: (11)C-l-deprenyl PET showed binding of rasagiline to MAO-B, confirming blocking of MAO-B sites after 10 d of treatment with 1 mg of rasagiline per day, with immediate post-rasagiline treatment tracer uptake and metabolism in the basal ganglia compatible only with nonspecific binding. rasagiline 144-154 monoamine oxidase B Homo sapiens 95-100 16204711-10 2005 This finding is compatible with the known rate of de novo synthesis of MAO-B, confirming the irreversible binding of rasagiline. rasagiline 117-127 monoamine oxidase B Homo sapiens 71-76 16204711-3 2005 In this study, we used (11)C-l-deprenyl PET to demonstrate the specific binding characteristics of the new irreversible selective MAO-B inhibitor rasagiline in 3 healthy volunteers. rasagiline 146-156 monoamine oxidase B Homo sapiens 130-135 16027398-1 2005 Rasagiline is a novel second-generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B). rasagiline 0-10 monoamine oxidase B Homo sapiens 98-122 16027398-1 2005 Rasagiline is a novel second-generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B). rasagiline 0-10 monoamine oxidase B Homo sapiens 124-129 16027398-3 2005 Rasagiline completely and selectively inhibits MAO-B with a potency 5 to 10 times greater than selegiline. rasagiline 0-10 monoamine oxidase B Homo sapiens 47-52 16007239-2 2005 The search for pharmacological treatments able to counteract the nigrostriatal degeneration, possibly by interfering with these phenomena, has recently raised considerable interest in rasagiline [R(+)-N-propargyl-1-aminoindan], a potent, selective, and irreversible inhibitor of monoamine oxidase B (MAO-B). rasagiline 184-194 monoamine oxidase B Homo sapiens 279-298 16007239-2 2005 The search for pharmacological treatments able to counteract the nigrostriatal degeneration, possibly by interfering with these phenomena, has recently raised considerable interest in rasagiline [R(+)-N-propargyl-1-aminoindan], a potent, selective, and irreversible inhibitor of monoamine oxidase B (MAO-B). rasagiline 184-194 monoamine oxidase B Homo sapiens 300-305 16110345-0 2005 Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. rasagiline 134-144 monoamine oxidase B Homo sapiens 95-100 16110345-1 2005 Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent, irreversible monoamine oxidase (MAO)-B inhibitor designed for use as an antiparkinsonian drug. rasagiline 0-10 monoamine oxidase B Homo sapiens 79-104 15663351-1 2005 Rasagiline is a second-generation potent, irreversible and selective inhibitor of monoamine-oxidase type B (MAO-B), which has been evaluated for the treatment of Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 82-106 15710852-1 2005 BACKGROUND: Rasagiline (n-propargyl-1[R]-aminoindan) mesylate is a novel irreversible selective monoamine oxidase type B inhibitor, previously demonstrated to improve symptoms in early Parkinson disease (PD). rasagiline 12-22 monoamine oxidase B Homo sapiens 96-120 16156677-10 2005 Rasagiline is a new MAO-B inhibitor that is not broken down to amphetamine derivatives and is indicated as both monotherapy in early PD and as adjunctive therapy in PD patients with motor fluctuations. rasagiline 0-10 monoamine oxidase B Homo sapiens 20-25 15850677-3 2005 Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor, anti-Parkinson drug. rasagiline 0-10 monoamine oxidase B Homo sapiens 78-103 15621213-0 2005 Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. rasagiline 49-59 monoamine oxidase B Homo sapiens 33-38 15621213-7 2005 We have therefore prepared a series of novel bifunctional drugs from the neuroprotective-antiapoptotic antiparkinson monoamine oxidase B inhibitor, rasagiline, by introducing a carbamate cholinesterase (ChE) inhibitory moiety into it. rasagiline 148-158 monoamine oxidase B Homo sapiens 117-136 15663351-1 2005 Rasagiline is a second-generation potent, irreversible and selective inhibitor of monoamine-oxidase type B (MAO-B), which has been evaluated for the treatment of Parkinson"s disease. rasagiline 0-10 monoamine oxidase B Homo sapiens 108-113 15027867-4 2004 Rasagiline has the highest specificity for MAO B, as demonstrated by a 100-fold higher inhibition potency (k(inact)/K(i)) compared to MAO A, with the remaining compounds exhibiting lower isozyme specificities. rasagiline 0-10 monoamine oxidase B Homo sapiens 43-48 15628826-0 2004 Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. rasagiline 64-74 monoamine oxidase B Homo sapiens 114-138 15628826-12 2004 In the repeated-dose study, all doses of rasagiline were well tolerated; almost full inhibition of platelet MAO-B activity was achieved with each rasagiline dose. rasagiline 41-51 monoamine oxidase B Homo sapiens 108-113 15573406-3 2005 Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor anti-Parkinson drug. rasagiline 0-10 monoamine oxidase B Homo sapiens 78-103 15628826-13 2004 CONCLUSION: Rasagiline is well tolerated at doses up to 20 mg once/day and is a potent inhibitor of platelet MAO-B in humans. rasagiline 12-22 monoamine oxidase B Homo sapiens 109-114 15300656-1 2004 Rasagiline (N-propargyl-1(R)-aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase-B inhibitor. rasagiline 0-10 monoamine oxidase B Homo sapiens 91-110 15147504-1 2004 We have recently shown that the anti-Parkinson-propargyl-containing monoamine oxidase B (MAO-B) inhibitor drug, rasagiline [N-propargyl-(1R)-aminoindan], and its cholinesterase inhibitor derivatives TV3326 and TV3279, regulate amyloid precursor protein (APP) processing by a protein kinase C (PKC)-dependent mechanism in SH-SY5Y neuroblastoma and PC12 cells. rasagiline 112-122 monoamine oxidase B Homo sapiens 68-87 15147504-1 2004 We have recently shown that the anti-Parkinson-propargyl-containing monoamine oxidase B (MAO-B) inhibitor drug, rasagiline [N-propargyl-(1R)-aminoindan], and its cholinesterase inhibitor derivatives TV3326 and TV3279, regulate amyloid precursor protein (APP) processing by a protein kinase C (PKC)-dependent mechanism in SH-SY5Y neuroblastoma and PC12 cells. rasagiline 112-122 monoamine oxidase B Homo sapiens 89-94 15027867-5 2004 MAO B and MAO A are more selective for the R-enantiomer (rasagiline) compared to the S-enantiomer (S-PAI) by 2500-fold and 17-fold, respectively. rasagiline 57-67 monoamine oxidase B Homo sapiens 0-5 15027867-6 2004 Differences in UV/vis and CD spectral data of the complexes of the studied compounds with both MAO A and MAO B are interpreted in light of crystallographic data of complexes of MAO B with rasagiline and its analogues (Binda, C.; et al. rasagiline 188-198 monoamine oxidase B Homo sapiens 105-110 15027867-6 2004 Differences in UV/vis and CD spectral data of the complexes of the studied compounds with both MAO A and MAO B are interpreted in light of crystallographic data of complexes of MAO B with rasagiline and its analogues (Binda, C.; et al. rasagiline 188-198 monoamine oxidase B Homo sapiens 177-182 12090555-2 2002 Rasagiline is a selective and potent irreversible MAO(B) inhibitor which is under development by Teva for the treatment of neurological diseases. rasagiline 0-10 monoamine oxidase B Homo sapiens 50-56 14555244-1 2003 The anti-Parkinson drug, rasagiline, a irreversible propargyl possessing monoamine oxidase B inhibitor can protect neurons in vitro and in vivo from a variety of neurotoxic insults including SIN-1, glutamate, the parkinsonism inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, N-methyl-(R)-salsolinol and including beta amyloid protein. rasagiline 25-35 monoamine oxidase B Homo sapiens 73-92 12470183-2 2002 OBJECTIVE: To evaluate the safety and efficacy of the selective monoamine oxidase type B inhibitor rasagiline. rasagiline 99-109 monoamine oxidase B Homo sapiens 64-88 14696044-6 2004 To circumvent this obstacle, a novel MAO-B inhibitor, rasagiline, was developed. rasagiline 54-64 monoamine oxidase B Homo sapiens 37-42 19810877-3 2003 One such agent is the anti-Parkinson drug, rasagiline, a novel neuroprotective-antiapoptotic second-generation potent irreversible selective inhibitor of monoamine oxidase B. rasagiline 43-53 monoamine oxidase B Homo sapiens 154-173 12504917-3 2002 Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at MAO-B-selective doses. rasagiline 41-51 monoamine oxidase B Homo sapiens 118-123 9564630-0 1998 (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. rasagiline 33-43 monoamine oxidase B Homo sapiens 104-123 12044957-3 2002 We have therefore developed a number of novel drugs based on rasagiline (N-propargyl-1R-(+)-aminoindan), a potent anti-Parkinson-propargyl-containing MAO-B inhibitor drug with structural resemblance to selegiline, for the treatment of Alzheimer"s disease. rasagiline 61-71 monoamine oxidase B Homo sapiens 150-155 11575866-8 2000 Almost complete platelet MAO-B inhibition was obtained at all rasagiline doses. rasagiline 62-72 monoamine oxidase B Homo sapiens 25-30 34977548-4 2022 Therefore, we determined whether rasagiline, a common MAO-B inhibitor used in PD treatment, can contribute to cardiovascular autonomic BP dysregulation in patients with early or mild PD. rasagiline 33-43 monoamine oxidase B Homo sapiens 54-59 35447344-2 2022 Two propargylamine-containing MAO-B inhibitors, selegiline ((R)-deprenyl) and rasagiline, are currently used in the clinic for this purpose. rasagiline 78-88 monoamine oxidase B Homo sapiens 30-35 34352710-3 2021 Compound 20 exhibited the best activity and selectivity towards hMAO-B with IC50 value of 53 nM and selectivity index of 1122 folds over MAO-A, compared to the reference drugs rasagiline (IC50 = 66 nM) and selegiline (IC50 = 40 nM). rasagiline 176-186 monoamine oxidase B Homo sapiens 64-70 34290084-5 2021 Both inhibition of MAO-B by selegiline or rasagiline and siRNA-mediated knockdown of MAO-B facilitated alpha-syn secretion. rasagiline 42-52 monoamine oxidase B Homo sapiens 19-24 34784871-11 2021 Of monoamine oxidase B inhibitors, safinamide is the least susceptible for interaction with the tyramine-rich food, whereas selegiline and rasagiline may lose selectivity to monoamine oxidase B when administered in supratherapeutic doses. rasagiline 139-149 monoamine oxidase B Homo sapiens 174-193 34562673-4 2021 A selectivity study over hMAO-A revealed an excellent selectivity index of compound 5 (SI > 2375) with a 47-fold increase compared to rasagiline (II, a well-known MAO-B inhibitor, SI > 50). rasagiline 134-144 monoamine oxidase B Homo sapiens 163-168 33818516-9 2021 All the tested compounds were capable to inhibit human monoamine oxidase-B enzyme to a significant extent, however, compound 7 exerted the most prominent inhibitory activity, similar to selegiline and rasagiline. rasagiline 201-211 monoamine oxidase B Homo sapiens 55-74 35447344-4 2022 An important consideration is that selegiline and rasagiline display specificity for MAO-B over the MAO-A isoform thus reducing the risk of tyramine-induced changes in blood-pressure. rasagiline 50-60 monoamine oxidase B Homo sapiens 85-90 35203982-4 2022 To date, no DRT-related withdrawal syndrome has been described in PD patients who discontinue rasagiline, an irreversible inhibitor of monoamine oxidase-B (MAO-B). rasagiline 94-104 monoamine oxidase B Homo sapiens 135-154 35203982-4 2022 To date, no DRT-related withdrawal syndrome has been described in PD patients who discontinue rasagiline, an irreversible inhibitor of monoamine oxidase-B (MAO-B). rasagiline 94-104 monoamine oxidase B Homo sapiens 156-161